SCHEMBL6762228

SCHEMBL6762228

CN1CCCC1CCNC(=O)c1ccccc1Oc1nn(Cc2ccccc2)c2ccccc12

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACKR3 P25106 1/20 0.47
BCHE P06276 1/20 0.46
ACHE P22303 1/20 0.46
POLR1A O95602 1/20 0.45
CACNA1B Q00975 1/20 0.44
APBA1 Q02410 1/20 0.44
USP30 Q70CQ3 1/20 0.42
NPY1R P25929 1/20 0.42
MAPT P10636 1/20 0.41
HTT P42858 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
SIGMAR1 Q99720 2/20 0.41
METAP2 P50579 1/20 0.41
HTR6 P50406 2/20 0.41
KDM4E B2RXH2 1/20 0.40
GUCY1B2 O75343 1/20 0.40
CYP1A2 P05177 1/20 0.40
CHRM2 P08172 1/20 0.40
HTR1A P08908 1/20 0.40
ADRA2A P08913 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6764315 0.80 KDM4E (0.58) ACHEPOLR1AMAPTHTTL3MBTL1
SCHEMBL6762478 0.80 USP30 (0.44) ACHEUSP30MAPTHTTL3MBTL1
SCHEMBL6763004 0.79 MEN1 (0.47) ACHEMAPTHTTL3MBTL1SIGMAR1
SCHEMBL6766831 0.79 CYP1A2 (0.61) ACHEMAPTHTTL3MBTL1SIGMAR1
SCHEMBL6760247 0.76 SMN1; SMN2 (0.51) KDM4E
SCHEMBL6763555 0.76 CNR1 (0.56) ACHEMAPTHTTL3MBTL1KDM4E
SCHEMBL6764331 0.76 KDM4E (0.46) ACHEMAPTHTTL3MBTL1KDM4E
SCHEMBL8418112 0.74 ADRA1A (0.54) ACHESIGMAR1HTR6KDM4EGUCY1B2
SCHEMBL6760125 0.74 MAPT (0.46) BCHEACHEUSP30MAPTHTT
SCHEMBL6763571 0.72 CNR1 (0.41) ACHEUSP30MAPTHTTL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040048866-A1 Indazole derivatives that are activators of soluble guanylate cyclase ABBOTT LABORATORIES 2004-03-11 US claimed
US-20040048866-A1 Indazole derivatives that are activators of soluble guanylate cyclase ABBOTT LABORATORIES 2004-03-11 US disclosed
WO-2003076408-A2 INDAZOLE DERIVATIVES THAT ARE ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE ABBOTT LABORATORIES (US) 2003-09-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040048866-A1 Indazole derivatives that are activators of soluble guanylate cyclase GUCY1B1, GUCY1A1, GUCY1A2 ACKR3 1368/4885BCHE 2360/4885ACHE 710/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.